GSK's Blenrep shows strong survival benefit in myeloma study
reported positive results from its phase three 'DREAMM-7' trial on Thursday, highlighting a significant overall survival benefit for 'Blenrep', or belantamab mafodotin, in patients with relapsed or refractory multiple myeloma.
The FTSE 100 drugmaker said the trial, involving 494 participants, demonstrated that Blenrep combined with bortezomib and 'dexamethasone', or BorDex, achieved a statistically significant reduction in mortality risk compared to a standard treatment regimen of daratumumab plus BorDex.
It said the survival advantage, a key secondary endpoint of the trial, added to the growing evidence supporting Blenrep's clinical efficacy.
Detailed data from the interim analysis, including safety findings, was set to be presented at the American Society of Hematology Annual Meeting on 9 December.
The results would be submitted to health authorities globally to support regulatory filings in the US, EU, UK, Japan, Canada, and Switzerland, with China already granting breakthrough therapy designation and priority review for Blenrep in combination with BorDex based on the DREAMM-7 findings.
GSK said the DREAMM - 'DRiving Excellence in Approaches to Multiple Myeloma - programme, which included other phase three trials such as DREAMM-8, continued to explore Blenrep's potential in various therapeutic combinations and earlier stages of treatment.
Plans were also underway for a new phase three study in newly diagnosed, transplant-ineligible multiple myeloma patients by year-end.
Multiple myeloma, one of the most prevalent blood cancers worldwide, often develops resistance to existing therapies, underscoring the need for innovative treatments like Blenrep.
GSK's Blenrep, an antibody-drug conjugate targeting B-cell maturation antigen, is currently approved as a monotherapy in several markets, including Hong Kong and Israel.
"The overall survival results from the DREAMM-7 trial underscore the potential for this Blenrep combination to extend the lives of patients with relapsed/refractory multiple myeloma," said Hesham Abdullah, GSK's senior vice-president and global head of oncology research and development.
"This is a statistically significant and clinically meaningful advancement for patients and potentially transformative for treatment.
"We look forward to sharing these data with health authorities and presenting the full results at next month's American Society of Hematology Annual Meeting."
At 0819 GMT, shares in GSK were down 0.84% at 1,350.5p.
Reporting by Josh White for Sharecast.com.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.